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Duration of untreated psychosis and negative symptoms -A systematic review and meta-analysis of individual patient data
Introduction
Negative symptoms are a core component of the schizophrenia syndrome and are commonly described in terms of five dimensions: blunted affect, alogia, anhedonia, avolition and asociality (Blanchard et al., 2005; Kirkpatrick et al., 2006; Makinen et al., 2008) . Negative symptoms are associated with poor functional outcome (Malla et al., 2004) , cognitive deficits (Heydebrand et al., 2004) , social dysfunction and poor quality of life (Addington and Addington, 1993; Schmitz et al., 2007; Petersen et al., 2008) . Negative symptoms are common: the prevalence in short-term follow-up studies (up to 2.5 years) is about 45% (Pogue-Geile and Harrow, 1985; Malla et al., 2002 Malla et al., , 2004 , and in longer term studies (7.5-10 years) 20-30% (Herbener and Harrow, 2001) . Schizophrenia Research 142 (2012) 12-19 There is no established treatment for primary negative symptoms (Kirkpatrick et al., 2006; Buckley and Stahl, 2007) . Pharmacological treatments, such as antipsychotics have only a marginal impact on negative symptom severity (Leucht et al., 2011) . Some psychosocial treatment trials have shown an effect on negative symptoms. Cognitive behavioral therapy showed a positive effect on negative symptoms up to 24 months of follow-up (NICE, 2010) . In addition there have been three small but promising trials on peer support groups (Castelein et al., 2008) , music therapy (Gold et al., 2009 ) and body oriented psychosocial therapy (Rohricht and Priebe, 2006) .
Pending replication of these studies, it may be that the best way to deal with negative symptoms apart from cognitive therapy is prevention. Many countries have already adopted an early intervention approach to the treatment of psychosis on the basis that there is a robust association between duration of untreated psychosis and the long-term severity of positive symptoms. A similar association between negative symptoms and outcome would support early intervention for negative symptoms (Melle et al., 2008) .
So far two meta-analyses have examined the correlation between DUP and negative symptoms (Marshall et al., 2005; Melle et al., 2008) . The first by Marshall et al. reported an association at 6 and 12 months but not at baseline and 24 months (Marshall et al., 2005) . The second by Perkins et al. claimed that patients with shorter DUP experienced less negative symptoms at baseline and follow-up (Perkins, 2006) . While making a valuable contribution, both reviews share three limitations. First, neither study provided a precise analysis of the effect of DUP at long term follow-up, thus Marshall et al. did not consider data on negative symptoms beyond 24 months and Perkins et al. summarized data of all follow-up assessments varying from 3 months to 15 years into one combined effect size. Second, both studies relied exclusively on published data, which meant that they excluded a substantial number of studies that collected pertinent data but did not publish it in a format that could be used in their analyses. Third, both studies used combined correlation coefficients calculated by different techniques, for example parametric in some studies and non-parametric in others.
As a consequence of these limitations, neither study was able to consider the relationship over time i.e. the linearity of the relationship between DUP and negative symptoms. So far most studies did focus on the relationship between DUP and positive symptoms (Drake et al., 2000) . Not only a positive association was found in most studies but also a non-linearity of this relationship between DUP and positive symptoms. This means that in a patient with a DUP of less than 12 months, the effect of a DUP reduction of for example 2 months on positive symptoms would be greater than a two month reduction in someone with a DUP of more than 12 months. It is possible therefore that a similar non-linear relationship might exist with negative symptoms, with important clinical implications.
The present study therefore had three aims: (a) to provide a precise estimate of the correlation between DUP and negative symptoms by substantially increasing the amount of available data contributing to the analysis; (b) to see if the strength of any correlation attenuates at longer follow up intervals; (c) to determine whether the relationship between DUP and negative symptoms was non-linear.
Methods

Search strategy
The search aimed to detect all cohort studies that had examined DUP and negative symptoms in first episode psychotic patients, and were available for review up to March 2009. The search included the databases MEDLINE and PUBMED using the keywords "DUP" AND "psychosis" OR "schizophrenia" and the combination "duration" AND "untreated" AND "psychosis" OR "schizophrenia". In addition references cited in these papers were examined.
Inclusion criteria and data extraction
Studies were included if they met two criteria. First, participants had experienced a first episode of psychosis defined as: schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder or psychosis NOS, according to either the Diagnostic Statistical Manual (DSM-IV) or the International Classification of Diseases (ICD-10) classification systems. Second, DUP and negative symptoms had been measured using a standardized method (which for negative symptoms was one of the three commonly used scales in this area), i.e.: the Positive and Negative Symptom Scale (PANSS) (Kay et al., 1987) , the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1989) , or the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) . We included all follow-up studies regardless of research design.
Abstracts were screened independently by two reviewers (N.B. and R.K.), and copies were obtained of any papers describing potentially eligible studies. Each paper was assessed independently by two reviewers and any disagreements resolved by discussion with a third reviewer (L.W.) (for table of included studies see Appendix 1). To overcome the limitations of previous meta-analyses it was necessary to obtain a substantial dataset of individual patient data (IPD) from first-episode studies (Stewart and Parmar, 1993; Stewart and Tierney, 2002) . The authors of included studies were contacted and asked to provide anonymized individual patient data on: gender, age at onset, DUP, and negative symptom scores at baseline and all available follow-up points.
Analysis
We calculated the correlation between DUP and negative symptoms for short and long term follow up. We defined short-term follow up as between 12 and 24 months and long term follow up as 60 to 96 months. Studies of which a Spearman correlation was published were used for sensitivity analysis.
In cases where more than one assessment was available for short or long term follow up, we used the first assessment. The data were analyzed using a two-step approach. First, individual patient data from each study were analyzed using the non-parametric Spearman's Rank Correlation. We choose a non-parametric test because of the significant positive skew in the distribution of DUP. In the second step, a meta-analysis of the aggregated data produced for each study was performed using Comprehensive Meta-Analysis in order to summarize the correlations (CMA, version 2005, Biostat, Inc., Englewood, NJ, 2005) (Borenstein et al., 2009) . We used random effect models because of great differences between research designs. Correlation data were synthesized with Fisher's z transformation into a single correlation coefficient (r) with 95% confidence intervals (CI).
CMA also tests for the heterogeneity of the sample populations using I 2 , a test parameter, which evaluates the null hypothesis that all studies are assessing the same effect size. I 2 indicates the percentage of total variation across studies due to heterogeneity rather than chance, and ranges from 0% (no heterogeneity) to 100% (high heterogeneity). Values for I 2 of 25%, 50% and 75% are considered to represent low, moderate and high heterogeneity respectively (Higgins et al., 2003) .
A major concern when conducting a meta-analysis is publication bias: studies that report relatively large effect sizes are more likely to be published than studies with smaller effect sizes. If the included studies are a biased sample of all relevant studies, consequently the bias will be reflected in the mean effect computed by the meta-analysis. A funnel plot can be made to examine the publication bias using Comprehensive Meta-Analysis (CMA, version 2005 , Biostat, Inc., Englewood, NJ, 2005 .
We examined the linearity of the relationship between DUP and negative symptom change using the method developed by Drake (Drake et al., 2000) . We used a multilevel regression analysis (XTREG in STATA release 11.0) (Snijders and BRJ, 1999; StataCorp., 2009 ) to estimate the magnitude of the effect of DUP on negative symptom severity reduction after various periods of follow-up with the individuals nested within each study. Subsequently, explanatory variables (gender and age at onset) were added, as potential confounders. The skewed distribution of DUP was corrected by converting DUP to its logarithm (logDUP) thus allowing the use of parametric statistics. The change of negative symptoms from baseline to follow-up was calculated as a percentage of baseline negative symptom severity and added in the multilevel regression analysis as the dependent variable. We conducted the analysis for negative symptom change at short and long-term follow up, as defined above.
Results
Studies and patients
A total of 402 papers were identified by the search strategy, from which we identified 28 non-overlapping first episode studies that met inclusion criteria (see Appendix 1) (Montague et al., 1989; Barnes et al., 2000; Craig et al., 2000; de Haan et al., 2000; Drake et al., 2000; Ho et al., 2000; Larsen et al., 2000; Black et al., 2001; Verdoux et al., 2001; Cullberg et al., 2002; Malla et al., 2003; Addington et al., 2004; Sim et al., 2004; Chen et al., 2005; Harris et al., 2005; Manchanda et al., 2005; Melle et al., 2005; Oosthuizen et al., 2005; Petersen et al., 2005; Wade et al., 2005; Clarke et al., 2006; Ucok et al., 2006; Wunderink et al., 2006; Crespo-Facorro et al., 2007; Malla et al., 2007; Vyas et al., 2007; Gorna et al., 2008; Yamazawa et al., 2008) . The selected studies included a total of 3998 participants. Following written requests, authors of 16 studies submitted their data sets that covered a total of 3339 participants. From the 12 studies of which individual patient data were not available, 2 studies reported a Spearman correlation at short term follow-up (1-2 years). Table 1 shows the distribution of DUP, gender and age at onset of participants of whom individual patient data were available at baseline. The follow-up data of 2 studies were incomplete and therefore only baseline data were used in our analysis (Montague et al., 1989; Malla et al., 2003; Melle et al., 2004; Manchanda et al., 2005; Malla et al., 2007) .
The mean age at onset of participants was 26.0 years (SD = 8.9), and the mean DUP was 61.4 weeks (SD = 132.7 weeks, median DUP = 12.0 weeks). 59% of the participants at baseline were males. Ucok (Ucok et al., 2006) 4. Association between duration of untreated psychosis and negative symptoms Fig. 1 shows a summary of the correlations between DUP and negative symptoms at baseline and short (1-2 years) and long-term follow-up (5-8 years). The data show a statistically significant positive correlation between DUP and negative symptoms at baseline (Fisher's z = 0.117, 95%CI 0.064-0.17), at short-term follow-up (Fisher's z = 0.18, 95%CI 0.086-0.274) and at long-term follow-up (Fisher's z = 0.202, 95%CI 0.137 − 0.267). There is no evidence for attenuation in the strength of the association with longer follow up. Tests for heterogeneity showed that the studies were low to moderately heterogeneous (I 2 = 48% at baseline, 75.9% at short term, 27.3% at long term follow-up). A sensitivity analysis was done by adding the reported Spearman correlations to the meta-analysis at short term follow-up from the two studies of which individual patient data were not obtained (Sim et al., 2004; Oosthuizen et al., 2005; Subramaniam et al., 2007) . These two additional studies did not substantially alter the reported correlations of heterogeneity statistics (I 2 = 71.8%).
Predicted negative symptom change
2150 patients nested in 12 studies were included in the multilevel analysis to explore the effect of DUP on negative symptom reduction at short-term follow-up. The mean follow-up assessment was 15.5 months (95%CI 15.3-15.7). In the multilevel analysis for long-term follow-up, 795 individuals nested in 7 studies were included and the mean follow-up assessment was 71.4 months (95%CI 70.2-72.7). Figs. 2 and 3 show the percentage change in negative symptoms predicted by a given DUP at short and long-term follow-up respectively.
Discussion
The analysis showed that there is a significant positive association between DUP and negative symptoms at: baseline, short
Study name Statistics for each study Fisher's Z and 95% CI
Fisher's Standard Lower Upper Z error Variance limit limit
Addington (2004) 0,040 0,066 0,004 -0,088 0,168 Barnes (2000) -0,017 0,103 0,011 -0,219 0,185 Chen (2005) -0,057 0,105 0,011 -0,264 0,150 Clarke (2006) -0,029 0,083 0,007 -0,192 0,134 Craig (2000) 0,302 0,054 0,003 0,197 0,407 Cullberg (2002) 0,129 0,089 0,008 -0,045 0,303 Drake (2000) 0,061 0,063 0,004 -0,063 0,185 Gorna (2008) 0,254 0,110 0,012 0,038 0,471 Harris (2005) 0,186 0,056 0,003 0,076 0,297 0,145 0,083 0,007 -0,018 0,308 Manchanda (2005) 0,076 0,092 0,008 -0,104 0,257 Melle (2004) 0,122 0,059 0,003 0,007 0,236 Montague (1989) 0,276 0,098 0,010 0,084 0,468 Petersen (2005) 0,053 0,061 0,004 -0,067 0,173 Ucok (2006) 0,063 0,104 0,011 -0,141 0,267 Wunderink (2006) 0,184 0,081 0,007 0,025 0,344 0,117 0,027 0,001 0,064 0,170 -1,00 -0,50 0,00 0,50 1,00
Favours A Favours B correlation between DUP and negative symptoms at baseline
Study name Statistics for each study Fisher's Z and 95% CI
Fisher's Standard Lower Upper Z error Variance limit limit
Addington (2004) 0,125 0,073 0,005 -0,018 0,267 Barnes (2000) 0,263 0,103 0,011 0,061 0,465 Chen (2000) 0,324 0,105 0,011 0,117 0,530 Craig (2000) -0,062 0,063 0,004 -0,185 0,061 Gorna (2008) 0,175 0,111 0,012 -0,043 0,393 Harris (2005) 0,412 0,056 0,003 0,301 0,522 Manchanda (2005) 0,218 0,092 0,008 0,038 0,399 Melle (2004) 0,227 0,062 0,004 0,105 0,349 Petersen (2005) 0,127 0,048 0,002 0,032 0,222 Ucok (2006) -0,105 0,136 0,019 -0,372 0,161 Wunderink (2006) 0,224 0,092 0,009 0,042 0,405 0,180 0,048 0,002 0,086 0,274 -1,00 -0,50 0,00 0,50 1,00
Favours A Favours B correlation between DUP and negative symptoms at short term follow-up (1-2 year)
Study name Statistics for each study Fisher's Z and 95% CI
Fisher's Standard Lower Upper Z error Variance limit limit
Addington (2004) 0,438 0,146 0,021 0,152 0,724 Clarke (2000) 0,258 0,104 0,011 0,053 0,462 Cullberg (2002) 0,040 0,101 0,010 -0,157 0,237 Gorna (2008) 0,293 0,118 0,014 0,062 0,524 Harris (2005) 0,217 0,056 0,003 0,107 0,328 Petersen (2005) 0,160 0,048 0,002 0,066 0,255 Wunderink (2006) 0,219 0,099 0,010 0,025 0,414 0,202 0,033 0,001 0,137 0,267 -1,00 -0,50 0,00 0,50 1,00 correlation between DUP and negative symptoms at long term follow-up (5-8 years) Fig. 1 . Correlations between DUP and negative symptoms at baseline, after 1-2 years follow-up and after 5-8 years follow-up.
(1-2 years) and long-term (5-8 years) follow-up. The effect is non-linear: negative symptoms and DUP are positively associated if DUP was less than 9 months. For those patients with a DUP longer than 9 months negative symptoms are not associated linearly. A reduction in DUP in someone with a shorter DUP (i.e. less than 9 months) might therefore have a greater impact on negative symptoms than the same reduction in someone with a DUP greater than nine months. These findings are in accordance with the findings of the TIPS study and the study of Malla et al. (2002 Malla et al. ( , 2004 , both of which suggested that reduction of DUP may be as important for improving the severity of negative symptoms as it is for positive symptoms (Melle et al., 2008) . Our finding of a non-linear association between DUP and negative symptoms is similar to that reported by Drake et al. for total PANSS scores (Drake et al., 2000) albeit in a small sample with a short follow-up. The association between a longer DUP and persistence of negative symptoms (after 1-2 years) is consistent with the hypothesis that in many cases psychosis is a clinical manifestation of a progressive pathological process in which early detection and intervention could be effective in ameliorating the course of the disorder. Figs. 2  and 3 suggest the existence of a critical period of DUP of about 9 months in which the association with negative symptoms is particularly strong. This finding supports arguments for early detection and intervention programs, since apart from prevention, there is no evidence-based treatment for negative symptoms (Melle et al., 2008) . However, it is important to emphasize that this analysis does not prove that there is a causal association between DUP and negative symptoms.
An important strength of this study is the use of individual patient data (IPD). The use of IPD in meta-analyses (Stewart and Parmar, 1993; Stewart and Tierney, 2002) offers a greater resolution of effect size than meta-analyses based on study level data. Individual patient data permitted us to reanalyze all the data using the same method of correlation and to calculate correlations that had not been previously published. We were also able to combine data across studies to explore the relationship between DUP and negative symptoms.
As a result of obtaining individual patient data, this review has substantially increased the amount of information available for analysis. Consequently, it has extended the findings of previous meta-analyses by providing more precise estimates of the correlation between duration of untreated psychosis and negative symptoms, examining the correlation at both short and long-term follow up and exploring the linearity of the association. This is of clinical importance because the window of opportunity to intervene to improve the prognosis of psychosis is considered to last 3-5 years (Birchwood, 2000) .
The main limitation of the review is that data were obtained on only 16 of 28 eligible studies. The 12 studies not obtained included 659 patients. Three studies reported correlations between DUP and negative symptoms at 12 to 24 months of follow-up of which 2 were Spearman correlations. Adding data of these two studies in the meta-analysis did not substantially alter the reported correlations of heterogeneity statistics. We were not able to correct for possible confounding variables on the correlation between DUP and negative symptoms, such as drug use or premorbid adjustment because we did not have access to these data.
Previous studies have noted considerable variation in first episode psychosis cohorts , for example in: participant characteristics; instruments to assess symptoms; measures of DUP; and definitions of DUP. In this meta-analysis we included observational studies as well as interventional studies. No interventional studies targeting negative symptoms were included. Some studies rely entirely on the patients' own reports and thus reflect the onset of the subjective experiences of psychosis while most studies have validated ratings of DUP by including interviews with family members, hospital records and reviews after one year of follow-up. Despite these problems, this analysis detected only a mild to moderate degree of statistical heterogeneity between studies, at a level that was not sufficient to undermine the main findings. We conducted a funnel plot in order to test publication bias. The plot shows the presence of symmetry for all analysis. Since the sampling error is random, this underpins the idea that there is no substantial publication bias.
In summary, the relationship between DUP and negative symptoms has been underestimated, and is in fact strong and persistent. A DUP of less than 9 months appears to be a strong predictor of improvement of negative symptoms, while most patients with a DUP longer than 9 months show persistent negative symptoms. It is unknown to what extent reducing DUP will improve outcome. However efforts to shorten DUP might decrease negative symptom severity as has been done in the Scandinavian TIPS study (Melle et al., 2008) . The absence of substantially effective treatments for negative symptoms supports preventive interventions with the potential to ameliorate negative symptoms, e.g. by reducing DUP.
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